Nanotechnology in corneal neovascularization therapy - A review

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 124-134

  Gonzalez, Lilian ^a   Loza, Raymond J ^a   Han, Kyu Yeon ^a   Sunoqrot, Suhair ^b   Cunningham, Christy ^a   Purta, Patryk ^a   Drake, James ^a   Jain, Sandeep ^a   Hong, Seungpyo ^b   Chang, Jin Hong ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AGANIRSEN; BETAMETHASONE; BEVACIZUMAB; BEVASIRANIB; CORTISONE; CYCLODEXTRIN; CYCLOSPORIN; DENDRIMER; DEXAMETHASONE; EYE DROPS; GOLD NANOPARTICLE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INSULIN RECEPTOR SUBSTRATE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOSOME; METHYLPREDNISOLONE; NIOSOME; NONSTEROID ANTIINFLAMMATORY AGENT; PEGAPTANIB; PHOTOSENSITIZING AGENT; PREDNISOLONE; RANIBIZUMAB; SHORT HAIRPIN RNA; SILVER NANOPARTICLE; SMALL INTERFERING RNA; TRASTUZUMAB; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; AUTOPHOSPHORYLATION; BIOCOMPATIBILITY; BIODEGRADABILITY; BLINDNESS; CAUTERIZATION; CELL MIGRATION; CELL PROLIFERATION; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DNA FRAGMENTATION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MEMBRANE PERMEABILITY; MICROEMULSION; MULTICENTER STUDY (TOPIC); NANOMEDICINE; NANOTECHNOLOGY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CORNEAL NEOVASCULARIZATION; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84875008467     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0158     Document Type: Review

References (89)

1. Basavaraj, K.H. Nanotechnology in medicine and relevance to dermatology: present concepts. Indian J Dermatol. 57:169-174, 2012.
2. Taniguchi, N. On the basic voncept of nanotechnology. Proc. ICPE Tokyo. 2:18-23, 1974.
3. Brakmane, G., Winslet, M., & Seifalian, A.M. Systematic review: the applications of nanotechnology in gastroenterology. Aliment Pharmacol Ther. 36:213-221, 2012.
4. Azar, D.T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 104:264-302, 2006.
5. Menzel-Severing, J. Emerging techniques to treat corneal neovascularisation. Eye (Lond). 26:2-12, 2012.
6. Tshionyi, M., Shay, E., Lunde, E., et al. Hemangiogenesis and lymphangiogenesis in corneal pathology. Cornea. 31:74-80, 2012.
7. Tan, D.T., Dart, J.K., Holland, E.J., et al. Corneal transplantation. Lancet. 379:1749-1761, 2012.
8. Liu, S., Jones, L. and Gu, F.X. Nanomaterials for ocular drug delivery. Macromol Biosci. 12:608-620, 2012.
9. Chang, J.H., Gabison, E.E., Kato, T., et al. Corneal neovascularization. Curr Opin Ophthalmol. 12:242-249, 2001.
10. Ding, H., Portilla-Arias, J., Patil, R., et al. The optimization of polymalic acid peptide copolymers for endosomolytic drug delivery. Biomaterials. 32:5269-5278, 2011.
11. Ding, H., Inoue, S., Ljubimov, A.V., et al. Inhibition of brain tumor growth by intravenous poly (beta-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected]. Proc Natl Acad Sci U S A. 107:18143-18148, 2010.
12. Stromblad, S., & Cheresh, D.A. Integrins, angiogenesis and vascular cell survival. Chem Biol. 3:881-885, 1996.
13. Lee, H.S., & Chung, S.K. The effect of subconjunctival suramin on corneal neovascularization in rabbits. Cornea. 29:86-92, 2010.
14. Shakiba, Y., Mansouri, K., Arshadi, D., et al. Corneal neovascularization: molecular events and therapeutic options. Recent Pat Inflamm Allergy Drug Discov. 3:221-231, 2009.
15. Ellenberg, D., Azar, D.T., Hallak, J.A., et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res. 29:208-248, 2010.
16. Onguchi, T., Han, K.Y., Chang, J.H., et al. Membrane type-1 matrix metalloproteinase potentiates basic fibroblast growth factor-induced corneal neovascularization. Am J Pathol. 174:1564-1571, 2009.
17. Kato, T., Kure, T., Chang, J.H., et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 508:187-190, 2001.
18. Han, K.Y., Fahd, D.C., Tshionyi, M., et al. MT1-MMP modulates bFGF-induced VEGF-A expression in corneal fibroblasts. Protein Pept Lett. 2012.
19. Chang, J.H., Garg, N.K., Lunde, E., et al. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 57:415-429, 2012.
20. Stevenson, W., Cheng, S.F., Dastjerdi, M.H., et al. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (lucentis) vs bevacizumab (avastin). Ocul Surf. 10:67-83, 2012.
21. Thompson, M., & Eadie, S. Kerato-conjunctivitis sicca and rheumatoid arthritis. Ann Rheum Dis. 15:21-25, 1956.
22. Felipe, A.F., Abazari, A., Hammersmith, K.M., et al. Corneal changes in ectrodactyly-ectodermal dysplasia-cleft lip and palate syndrome: case series and literature review. Int Ophthalmol, 2012.
23. Di Tommaso, C., Bourges, J.L., Valamanesh, F., et al. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm. 81:257-264, 2012.
24. Chen, P., Yin, H., Wang, Y., et al. Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1alpha in a mouse model of closed eye contact lens wear. Mol Vis. 18:864-873, 2012.
25. Gaudana, R., Jwala, J., Boddu, S.H., et al. Recent perspectives in ocular drug delivery. Pharm Res. 26:1197-1216, 2009.
26. Govindarajan, B., & Gipson, I.K. Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res. 90:655-663, 2010.
27. Albertsmeyer, A.C., Kakkassery, V., Spurr-Michaud, S., et al. Effect of pro-inflammatory mediators on membraneassociated mucins expressed by human ocular surface epithelial cells. Exp Eye Res. 90:444-451, 2010.
28. Gipson, I.K. The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture. Invest Ophthalmol Vis Sci. 48:4390; 4391-4398, 2007.
29. Gipson, I.K. Distribution of mucins at the ocular surface. Exp Eye Res. 78:379-388, 2004.
30. Rawas-Qalaji, M., & Williams, C.A. Advances in ocular drug delivery. Curr Eye Res. 37:345-356, 2012.
31. Lee, S.S., Hughes, P.M., & Robinson, M.R., Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr Opin Ophthalmol. 20:511-5119, 2009.
32. Hashemian, M.N., Moghimi, S., Kiumehr, S., et al. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res. 42:90-95, 2009.
33. Sener, E., Yuksel, N., Yildiz, D.K., et al. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Curr Eye Res. 36:1005-10013, 2011.
34. Bock, F., Konig, Y., Kruse, F., et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 246:281-284, 2008.
35. Dykxhoorn, D.M., Novina, C.D., & Sharp, P.A. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 4:457-467, 2003.
36. Fire, A., Xu, S., Montgomery, M.K., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806-811, 1998.
37. Cho, W.G., Albuquerque, R.J., Kleinman, M.E., et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A. 106:7137-7142, 2009.
38. Tarallo, V., Hirano, Y., Gelfand, B.D., et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell. 149:847-859, 2012.
39. Han, K.Y., Azar, D.T., Sabri, A., et al. Characterization of the interaction between endostatin short peptide and VEGF receptor. Protein Pept Lett. 2012.
40. Chang, J.H., Javier, J.A., Chang, G.Y., et al. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett. 579: 3601-3606, 2005.
41. Lin, H.C., Chang, J.H., Jain, S., et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci. 42:2517-2524, 2001.
42. Zhang, Z., Ma, J.X., Gao, G., et al. Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization. Invest Ophthalmol Vis Sci. 46:4062-71, 2005.
43. Andrieu-Soler, C., Berdugo, M., Doat, M., et al. Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci. 46:4072-4078, 2005.
44. Gupta, D., & Illingworth, C. Treatments for corneal neovascularization: a review. Cornea. 2011.
45. Cursiefen, C., Wenkel, H., Martus, P., et al. Impact of shortterm versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol. 239:514-521, 2001.
46. Monnier, Y., Zaric, J. and Ruegg, C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 4:31-38, 2005.
47. Han, Y., Shao, Y., Lin, Z., et al. Netrin-1 simultaneously suppresses corneal inflammation and neovascularization. Invest Ophthalmol Vis Sci. 53:1285-1295, 2012.
48. Liu, X., Lin, Z., Zhou, T., et al. Anti-Angiogenic and antiinflammatory effects of SERPINA3K on corneal injury. PLoS One. 6:e16712, 2011.
49. Nirankari, V.S., Baer, J.C. Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty. Ophthalmology. 93:1304-1309, 1986.
50. Pillai, C.T., Dua, H.S., & Hossain, P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 41:2148-53, 2000
51. Koenig, Y., Bock, F., Kruse, F.E., et al. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea. 2012.
52. Peer, D., Karp, J.M., Hong, S., et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751-760, 2007.
53. Duncan, R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2:347-360, 2003.
54. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 6:688-701, 2006.
55. Gref, R., Minamitake, Y., Peracchia, M.T., et al. Biodegradable long-circulating polymeric nanospheres. Science. 263:1600-1603, 1994.
56. Shao, T., Li, X., & Ge, J., Target drug delivery system as a new scarring modulation after glaucoma filtration surgery. Diagn Pathol. 6:64, 2011.
57. Sahoo, S.K., Dilnawaz, F., & Krishnakumar, S. Nanotechnology in ocular drug delivery. Drug Discov Today. 13: 144-151, 2008.
58. Bhatta, R.S., Chandasana, H., Chhonker, Y.S., et al. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies. Int J Pharm. 2012.
59. Prieto, E., Puente, B., Uixera, A., et al. Gantrez AN nanoparticles for ocular delivery of memantine: in vitro release evaluation in albino rabbits. Ophthalmic Res. 48:109-117, 2012.
60. Kim, J.H., Kim, J.H., Kim, K.W., et al. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology. 20:505101, 2009.
61. Loo, S.C., Tan, Z.Y., Chow, Y.J., et al. Drug release from irradiated PLGA and PLLA multi-layered films. J Pharm Sci. 99:3060-3071, 2010.
62. Ciolino, J.B., Hoare, T.R., Iwata, N.G., et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci. 50:3346-3352, 2009.
63. Kataoka, K., Harada, A. and Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 47:113-131, 2001.
64. Aliabadi, H.M., & Lavasanifar, A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv. 3:139-162, 2006.
65. Croy, S.R., & Kwon, G.S. Polymeric micelles for drug delivery. Curr Pharm Des. 12:4669-4684, 2006.
66. Civiale, C., Licciardi, M., Cavallaro, G., et al. Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. Int J Pharm. 378:177-186, 2009.
67. Lawrence, M.J., & Rees, G.D. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 45:89-121, 2000.
68. Sultana, Y., Maurya, D.P., Iqbal, Z., et al. Nanotechnology in ocular delivery: current and future directions. Drugs Today (Barc). 47:441-55, 2011.
69. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 4:145-160, 2005.
70. Thrimawithana, T.R., Young, S., Bunt, C.R., et al. Drug delivery to the posterior segment of the eye. Drug Discov Today. 16:270-277, 2011.
71. Shatalebi, M.A., Mostafavi, S.A., & Moghaddas, A. Niosome as a drug carrier for topical delivery of N-Acetyl glucosamine. Res Pharm Sci. 5:107-17, 2010.
72. Kazi, K.M., Mandal, A.S., Biswas, N., et al. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res. 1:374-380, 2010.
73. Yao, C.,Wang,W., Zhou, X., et al. Effects of poly(amidoamine) dendrimers on ocular absorption of puerarin using microdialysis. J Ocul Pharmacol Ther. 27:565-569, 2011.
74. Spataro, G., Malecaze, F., Turrin, C.O., et al. Designing dendrimers for ocular drug delivery. Eur J Med Chem. 45: 326-334, 2010.
75. Shi, X., Wang, S.H., Lee, I., et al. Comparison of the internalization of targeted dendrimers and dendrimer-entrapped gold nanoparticles into cancer cells. Biopolymers. 91:936-942, 2009.
76. Majoros, I.J., Williams, C.R., Tomalia, D.A., et al. New dendrimers: synthesis and characterization of POPAM-PAMAM hybrid dendrimers. Macromolecules. 41:8372-8379, 2008.
77. Siefert, B., Pleyer, U., Muller, M., et al. Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide. J Ocul Pharmacol Ther. 15:429-438, 1999.
78. Davis, M.E., & Brewster, M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 3:1023-1035, 2004.
79. Kemp, M.M., Kumar, A., Mousa, S., et al. Gold and silver nanoparticles conjugated with heparin derivative possess anti-Angiogenesis properties. Nanotechnology. 20:455104, 2009.
80. Kim, J.H., Kim, M.H., Jo, D.H., et al. The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials. 32:1865-1871, 2011.
81. Oner, V., Kucukerdonmez, C., Akova, Y.A., et al. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model. Ophthalmic Res. 48:118-123, 2012.
82. Singh, S.R., Grossniklaus, H.E., Kang, S.J., et al. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laserinduced CNV. Gene Ther. 16:645-659, 2009.
83. Kaplitt, M.G., Leone, P., Samulski, R.J., et al. Long-term gene expression and phenotypic correction using adenoassociated virus vectors in the mammalian brain. Nat Genet. 8:148-154, 1994.
84. Stechschulte, S.U., Joussen, A.M., von Recum, H.A., et al. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci. 42:1975-1979, 2001.
85. Iriyama, A., Usui, T., Yanagi, Y., et al. Gene transfer using micellar nanovectors inhibits corneal neovascularization in vivo. Cornea. 30:1423-1427, 2011.
86. Sugisaki, K., Usui, T., Nishiyama, N., et al. Photodynamic therapy for corneal neovascularization using polymeric micelles encapsulating dendrimer porphyrins. Invest Ophthalmol Vis Sci. 49:894-899, 2008.
87. Li, W., Feng, S.S. and Guo, Y. Block copolymer micelles for nanomedicine. Nanomedicine (Lond). 7:169-172, 2012.
88. Jani, P.D., Singh, N., Jenkins, C., et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 48:2030-2036, 2007.
89. Qazi, Y., Stagg, B., Singh, N., et al. Nanoparticle-mediated delivery of shRNA.VEGF-A plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci. 53:2837-2844, 2012.